Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accounts Payables: 2010-2024

Historic Accounts Payables for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $5.4 million.

  • Lineage Cell Therapeutics' Accounts Payables rose 1.63% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 1.63%. This contributed to the annual value of $5.4 million for FY2024, which is 13.29% down from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' Accounts Payables is $5.4 million, which was down 13.29% from $6.3 million recorded in FY2023.
  • Lineage Cell Therapeutics' Accounts Payables' 5-year high stood at $28.0 million during FY2021, with a 5-year trough of $5.4 million in FY2024.
  • Over the past 3 years, Lineage Cell Therapeutics' median Accounts Payables value was $6.3 million (recorded in 2023), while the average stood at $6.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 310.52% in 2021, then slumped by 69.22% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Accounts Payables stood at $6.8 million in 2020, then soared by 310.52% to $28.0 million in 2021, then slumped by 69.22% to $8.6 million in 2022, then dropped by 27.16% to $6.3 million in 2023, then fell by 13.29% to $5.4 million in 2024.